Patient’s doctor should submit a physician’s order, insurance information, clinical notes, and medication, such as somatostatin therapies. PET center scheduling office will obtain insurance authorization. Gallium 68 PET/CT scans are scheduled Monday-Friday 6:30am-3:30pm
Johns Hopkins is a leader in the development and use of theranostics. The Division of Nuclear Medicine and Molecular Imaging has pioneered the development of imaging and theranostic agents for prostate cancer.
Our Center was the first in the State of Maryland to offer 117Lu-DOTATATE, with several hundred infusions performed to date. As this field is rapidly evolving, new agents will become available. The Center will adopt them on an ongoing basis for safe, effective management of a variety of cancers.
Theranostics, a burgeoning new field arising from nuclear medicine, is the combination of imaging and molecular radiotherapy. Imaging, generally positron emission tomography (PET), is used to identify the tumor. The therapy in this case is a radiopharmaceutical – a radioactive drug that, like the PET agent that identified it, specifically targets cancer while leaving most normal, non-target tissues alone. Unlike external beam radiotherapy, molecular radiotherapy carries the radioactivity, in the form of particles that are emitted from the radiopharmaceutical, directly to the tumor.
The Center operates in close coordination with our partners in the Sidney Kimmel Comprehensive Cancer Center. Our most active service at present implements 177Lu-DOTATATE, for patients with neuroendocrine tumors. A 68Ga-DOTATATE PET scan is used to identify tumors that will concentrate the corresponding therapeutic (177Lu-DOTATATE). Having such tumors is one of the criteria to be a candidate for this therapy. We have found this therapy to be safe and well tolerated, with patients frequently relating an improved quality of life.
Lutetium Lu 177 vipivotide tetraxetan
Like Lutetium Lu 177 dotatate, Lutetium Lu 177 vipivotide tetraxetan is administered by brief intravenous infusion on an outpatient basis. It is provided in up to six cycles of therapy, which are eight weeks apart. Pluvicto concentrates within prostate tumors that express the prostate-specific membrane antigen (PSMA). Accordingly, candidates for this therapy must undergo a PSMA PET scan that shows that their tumor(s) concentrate the PET agent, which would be indication that they would also concentrate the corresponding radiotherapeutic. Pluvicto is well-tolerated, with few side effects, can provide relief from pain and may prolong life.
Radioligand is a nuclear medicine treatment that uses targeted radiation to kill cancer cells from within.
Radioligand targets molecule that binds to specific receptors (somatostatin) on the tumor cell surface and a radioactive particle that can kill the tumor cell.
Radioligand is a treatment for adults with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that test positive for somatostatin receptors.
Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) receiving Lutathera® ([177Lu]DOTATATE) at Johns Hopkins Hospital must first be evaluated by a medical oncologist at Johns Hopkins for consultation. The medical oncologist will review the case with the Johns Hopkins nuclear medicine team. If all are in agreement that Radioligand therapy with Lutathera® is appropriate, the nuclear medicine team will pursue the additional required assessments. Patients must have somatostatin receptor-positive GEP-NETs, with a positive result on a somatostatin receptor-specific imaging study, e.g., NETSPOT™ ([68Ga]DOTATATE PET/CT, documented prior to therapy.
The Johns Hopkins Hospital nuclear medicine team will obtain insurance preauthorization prior to scheduling the first Radioligand treatment. Patients, or their referring physician, may schedule the initial consultation. A copy of the patient’s medical records will be requested by the nuclear medicine team, including clinic notes, the pathology report confirming diagnosis, imaging, and laboratory tests.
Please inquire about ongoing clinical research in theranostics 443-253-3894
“Perhaps most gratifying about the radiotheranostics service is how over the course of therapy we often see a vast improvement in the quality of life of our patients.”
- Martin Pomper, M.D., Ph.D.
Nuclear Medicine Radiotheranostic Center Director
Your Treatment Team
Danielle Rill, B.S.,CNMT,R.T.(N)(CT)(ARRT)
Senior Radiotheranostics Technologist
Avery Spitz, RN,MSN
Radiotheranostics Nurse Navigator
Jeffrey Young, B.S.,CNMT,R.T.(CT)(ARRT)